Trial Profile

A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 02 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Decitabine (Primary) ; LYT 200 (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Adverse reactions
Sponsors PureTech Health

28 May 2025 Planned End Date changed from 1 May 2025 to 1 Mar 2026.
28 May 2025 Planned primary completion date changed from 1 Feb 2025 to 1 Dec 2025.
10 Dec 2024 Results (n=37) the safety, tolerability, and pharmacokinetics (PK) of LYT-200 and LYT-200 + VEN/HMA, in R/R AML/high-risk MDS, presented at the 66th American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com